Abzena launches new analytical platform
LabZient is an analytical platform to expedite the path to IND for antibodies
16 Feb 2024
Abzena has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs.
LabZient combines predictive in-silico evaluation with well established and vetted laboratory methods that de-risk the application of platform analytical procedures. In doing so, LabZient removes the need for extensive method qualification testing and enables antibody critical quality attributes (CQA) to be measured with a high degree of certainty early in the development process.
Dr Louise Duffy, Chief Technology Officer at Abzena, said, “By leveraging our extensive analytical expertise, laboratory methods, development data, and method qualification results, we’ve created a standardized, automated process that predicts how certain antibody molecules will behave, based on a structural assessment. This unique approach provides customers with critical data sooner, allowing them to make more informed decisions earlier in their development timeline that can ensure greater downstream clinical and commercial success.”
Assessments to date indicate that the LabZient platform methods are fit-for-purpose across a wide range of antibodies including monoclonal antibodies (mAbs), antibody fragments (Fabs) and bispecifics. Abzena will be expanding the application of this approach to antibody drug conjugates (ADCs) in the near future.